11/20
08:22 am
tvgn
Tevogen Bio (NASDAQ:TVGN) had its price target lowered by analysts at D. Boral Capital from $10.00 to $5.00. They now have a "buy" rating on the stock.
High
Report
Tevogen Bio (NASDAQ:TVGN) had its price target lowered by analysts at D. Boral Capital from $10.00 to $5.00. They now have a "buy" rating on the stock.
11/14
02:39 pm
tvgn
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q [Yahoo! Finance]
Low
Report
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q [Yahoo! Finance]
11/14
02:32 pm
tvgn
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
Low
Report
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
11/5
03:20 pm
tvgn
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
Medium
Report
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
11/3
02:45 pm
tvgn
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
Low
Report
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
10/29
12:35 pm
tvgn
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
Medium
Report
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
10/15
04:14 pm
tvgn
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest [Yahoo! Finance]
Medium
Report
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest [Yahoo! Finance]
10/15
03:50 pm
tvgn
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
Low
Report
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
9/26
09:13 am
tvgn
This Week In Cloud AI - Navigating The AI Investment Shift Toward Sustainable Growth [Yahoo! Finance]
Low
Report
This Week In Cloud AI - Navigating The AI Investment Shift Toward Sustainable Growth [Yahoo! Finance]
9/25
09:19 am
tvgn
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion [Yahoo! Finance]
Low
Report
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion [Yahoo! Finance]
9/25
08:30 am
tvgn
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
Medium
Report
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
9/23
08:42 am
tvgn
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID [Yahoo! Finance]
Medium
Report
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID [Yahoo! Finance]
9/23
08:30 am
tvgn
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
Medium
Report
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
9/19
03:40 pm
tvgn
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
Low
Report
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
9/10
11:59 am
tvgn
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
Low
Report
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
9/9
03:15 pm
tvgn
Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
Low
Report
Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
9/8
09:27 am
tvgn
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
Medium
Report
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform